Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.
about
EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinibThe role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancerNon-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancerThe distinctive nature of adenocarcinoma of the lungRole of rebiopsy in relapsed non-small cell lung cancer for directing oncology treatmentsEGFR mutations as a prognostic and predictive marker in non-small-cell lung cancerOptimal therapeutic strategy for non-small cell lung cancer with mutated epidermal growth factor receptorNeoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancerManagement of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancerIrreversible EGFR-TKIs: dreaming perfectionMolecular pathology of lung cancer: key to personalized medicine.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsMechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis.Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitorsUnravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsPersonalized treatment of advanced non-small-cell lung cancer in routine clinical practiceMechanisms of resistance to EGFR-targeted drugs: lung cancerRe-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired ResistanceA novel classification of lung cancer into molecular subtypesClinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations.Update: the status of clinical trials with kinase inhibitors in thyroid cancerMeta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs.Molecular pathways and therapeutic targets in lung cancerIntratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?Synthesis and biochemical characterization of EGF receptor in a water-soluble membrane model systemEpidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatmentA crowded, but still varied, space: brigatinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer.Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling.Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutationsNovel agents in development for advanced non-small cell lung cancer.AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC.Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib.Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer.New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer.
P2860
Q24606177-3DEFCD13-F858-4E04-97EB-6EA7BAC13FC6Q26740529-9D880C5C-1902-46FB-A19B-5DF555907B79Q26741814-9E71FF17-3296-44DE-BE4C-CE76B5EB9788Q26775376-94FA94EA-F485-4A3D-B479-CEF2182DE130Q26781159-014EF5CC-9A43-41B5-8C89-F4A8B1BA935AQ26852206-E9E059F0-26FD-4423-BCB6-6D8D54575913Q26852507-29EAFC79-2EA6-4F72-A280-B877BAB826F1Q26859993-FCE7A37F-476A-4E48-AFEC-44F3B2C7DE8CQ26863742-C20A2807-5A9D-4210-9C37-01BC391C16F5Q26865779-013CEADB-4010-4F77-9B80-C8266FEB98B4Q26866186-ADB109C5-2A09-4AAA-9BFF-02D7D3BDDEABQ27691299-8E0BCA5A-E6B1-4701-8261-F55A53AA8D4BQ27851633-9E700F77-C403-425D-A356-5ABA7A0F6B02Q27851702-1E245FDD-1323-43A1-BBDA-27BF00B29222Q27852116-9BBD661A-5954-48A6-AEE0-5557EB3CB41DQ27852950-E2EE275D-3280-4BA9-B9A0-BB3E7FEB3BE6Q27853015-2FFEA955-B8C8-4F91-93E4-8AA3DF5209B1Q28069708-C311807A-C4C5-4600-940B-431B47231081Q28075291-662AF0E4-2A2E-4F66-BB84-8E39C4FA0D5DQ28075800-2786DC32-7F52-4DE9-BF07-2CDCD77F81C5Q28077415-BF762C9E-ABED-4044-8479-B0B1101C36F2Q28083239-1BFA3B9A-AC34-4C98-87ED-58EEECA18627Q28731874-3EF078AE-0968-4784-BDDD-BF89D84A4DEAQ31158651-209A6BCF-F6C9-4EE6-AAF9-8A7BAC0C688FQ33570056-E1579C9E-3C84-49F5-93C8-6448BB16A3C8Q33621143-CB38E0D3-CF87-4B98-968A-5C07AE0435E4Q33688872-C81CD8CD-AEC9-4F85-908F-D75D6237FD46Q33700689-4B27375E-01ED-409A-8855-473D5168F387Q33769117-2DE31B99-8ED6-4753-A1AD-5046614F7246Q33813089-97116BAA-E743-453E-A40B-8600FCBFC7B3Q33865475-89F9B802-ECC8-4EFE-8051-C84432346BDDQ34093266-F7D981C6-7AC6-4684-A2D8-79D56A1D8947Q34135471-A77C8CE9-F71A-41C5-9F62-51D31D855A12Q34389263-803140A5-BE4F-4CC1-A77D-62E527E394C4Q34497467-14C37F75-D2B1-46FC-87DB-7ADFF7AD1210Q34535332-AE56CEEE-E35B-4096-96A0-CC4E823FEDD9Q34762839-E6E53EEB-D716-412E-8200-60EEF1DA5647Q35004426-C09EA67E-D1B0-4305-B330-312B0CCAD670Q35076221-6270C115-E2BE-4BCB-BDFD-9290296BA71FQ35196345-FC69D8DB-4BA3-4EBC-AC6D-F8733CCD1288
P2860
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Acquired resistance to EGFR ty ...... harboring the T790M mutation.
@ast
Acquired resistance to EGFR ty ...... harboring the T790M mutation.
@en
Acquired resistance to EGFR ty ...... harboring the T790M mutation.
@nl
type
label
Acquired resistance to EGFR ty ...... harboring the T790M mutation.
@ast
Acquired resistance to EGFR ty ...... harboring the T790M mutation.
@en
Acquired resistance to EGFR ty ...... harboring the T790M mutation.
@nl
prefLabel
Acquired resistance to EGFR ty ...... harboring the T790M mutation.
@ast
Acquired resistance to EGFR ty ...... harboring the T790M mutation.
@en
Acquired resistance to EGFR ty ...... harboring the T790M mutation.
@nl
P2093
P2860
P50
P1476
Acquired resistance to EGFR ty ...... harboring the T790M mutation.
@en
P2093
Camelia S Sima
Geoffrey R Oxnard
Gregory J Riely
Maria E Arcila
Mark G Kris
Vincent A Miller
P2860
P304
P356
10.1158/1078-0432.CCR-10-2692
P407
P577
2010-12-06T00:00:00Z